Spero Therapeutics (NASDAQ:SPRO) Issues Earnings Results

Spero Therapeutics (NASDAQ:SPRO) announced its quarterly earnings results on Wednesday. The company reported ($0.13) EPS for the quarter, topping the consensus estimate of ($0.18) by $0.05, FiscalAI reports. Spero Therapeutics had a net margin of 12.83% and a return on equity of 22.53%. The company had revenue of $0.26 million for the quarter, compared to analyst estimates of $43.34 million.

Spero Therapeutics Price Performance

Shares of Spero Therapeutics stock traded up $0.19 on Thursday, hitting $2.63. The company had a trading volume of 1,039,834 shares, compared to its average volume of 371,612. The firm has a market capitalization of $151.99 million, a P/E ratio of 21.88 and a beta of 1.43. Spero Therapeutics has a twelve month low of $0.63 and a twelve month high of $3.22. The stock has a 50-day moving average of $2.54 and a 200-day moving average of $2.42.

Analyst Ratings Changes

A number of research firms recently issued reports on SPRO. Weiss Ratings restated a “sell (d-)” rating on shares of Spero Therapeutics in a research report on Tuesday, April 21st. Wall Street Zen raised shares of Spero Therapeutics from a “hold” rating to a “strong-buy” rating in a report on Sunday, March 29th. One research analyst has rated the stock with a Hold rating and one has given a Sell rating to the stock. According to MarketBeat.com, the company currently has an average rating of “Reduce”.

Insider Buying and Selling at Spero Therapeutics

In related news, insider Esther Rajavelu sold 25,240 shares of the firm’s stock in a transaction on Monday, May 4th. The shares were sold at an average price of $2.51, for a total value of $63,352.40. Following the completion of the transaction, the insider owned 986,851 shares of the company’s stock, valued at approximately $2,476,996.01. This trade represents a 2.49% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. The sale was made to cover tax withholding obligations related to the vesting of equity awards. 5.50% of the stock is owned by company insiders.

Institutional Investors Weigh In On Spero Therapeutics

Hedge funds and other institutional investors have recently added to or reduced their stakes in the business. XTX Topco Ltd bought a new stake in Spero Therapeutics during the second quarter worth $100,000. Invesco Ltd. bought a new position in shares of Spero Therapeutics in the second quarter valued at about $43,000. Vanguard Group Inc. raised its position in shares of Spero Therapeutics by 2.0% in the third quarter. Vanguard Group Inc. now owns 1,989,855 shares of the company’s stock valued at $3,741,000 after purchasing an additional 39,474 shares during the period. Dimensional Fund Advisors LP bought a new position in shares of Spero Therapeutics in the third quarter valued at about $55,000. Finally, Arrowstreet Capital Limited Partnership bought a new position in shares of Spero Therapeutics in the third quarter valued at about $283,000. 25.60% of the stock is currently owned by institutional investors and hedge funds.

Spero Therapeutics Company Profile

Spero Therapeutics is a clinical‐stage biopharmaceutical company focused on the discovery and development of novel therapies to address multidrug‐resistant bacterial infections. Headquartered in Boston, Massachusetts, the company aims to advance a pipeline of oral and intravenous antibiotic candidates designed to treat serious infectious diseases that pose significant public health challenges.

The company’s lead candidate, tebipenem HBr, is an oral carbapenem antibiotic being developed for the treatment of complicated urinary tract infections caused by resistant Gram‐negative pathogens.